PI
MACK

Putnam Investments’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Putnam Investments’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-22,761
Closed -$730K – 1326
2016
Q4 		$730K Sell
22,761
-314,610
-93% -$13.4M ﹤0.01% 1066
2016
Q3 		$16.9M Sell
337,371
-15,245
-4% -$633K 0.04% 305
2016
Q2 		$15M Buy
352,616
+13,136
+4% +$716K 0.04% 338
2016
Q1 		$22.4M Buy
339,480
+57,327
+20% +$2.99M 0.05% 272
2015
Q4 		$17.5M Buy
282,153
+183,820
+187% +$12.9M 0.04% 333
2015
Q3 		$6.58M Buy
98,333
+723
+0.7% +$59K 0.01% 580
2015
Q2 		$9.5M Sell
97,610
-199
-0.2% -$18.9K 0.02% 494
2015
Q1 		$9.14M Sell
97,809
-1,027
-1% -$87.4K 0.02% 537
2014
Q4 		$8.79M Sell
98,836
-79
-0.1% -$5.75K 0.02% 540
2014
Q3 		$6.83M Sell
98,915
-11,363
-10% -$607K 0.01% 633
2014
Q2 		$6.33M Sell
110,278
-19,432
-15% -$987K 0.01% 683
2014
Q1 		$5.14M Buy
129,710
+91,252
+237% +$3.9M 0.01% 743
2013
Q4 		$1.62M Buy
38,458
+328
+0.9% +$9.51K ﹤0.01% 1101
2013
Q3 		$1.14M Hold
38,130
– – ﹤0.01% 1189
2013
Q2 		$2.02M Buy
+38,130
New +$1.67M 0.01% 1050

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Putnam Investments's MACK Position: Q1 2017 in Review

Putnam Investments sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2017, closing a stake of 22,761 shares — an estimated $730K sold.

Putnam Investments first reported a position in MACK in Q2 2013 and held it in 15 quarters. The position peaked at $22.4M in Q1 2016. 116 funds tracked by Wall St. Rank hold MACK as of Q1 2017.

  • Putnam Investments reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Putnam Investments sold 22,761 Merrimack Pharmaceuticals, Inc. shares in Q1 2017, an estimated $730K.
  • Putnam Investments first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
  • Putnam Investments's Merrimack Pharmaceuticals, Inc. position peaked at $22.4M in Q1 2016.
  • 116 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2017.

Based on Putnam Investments's 13F filing for Q1 2017, filed 15 May 2017.